Vaginal products

Vaginal products - Medications

Bacterial Vaginosis
clindamycin (Cleocin)	metronidazole (Metrogel)
Vulvovaginal candidiasis
butoconazole (Femstat)	clotrimazole (mycelex, Gyne-Lotrimin)
miconazole (Monistat)	terconazole (Terazol)
tioconazole (Vagistat)

Bacterial Vaginosis

clindamycin (Cleocin):

Bacterial vaginosis: Intravaginal:
Suppositories:
Insert one ovule (100 mg clindamycin) daily into vagina at bedtime for 3 days

Cream:
Cleocin®: One full applicator inserted intravaginally once daily before bedtime for 3 or 7 consecutive days in nonpregnant patients or for 7 consecutive days in pregnant patients

Clindesse™: One full applicator inserted intravaginally as a single dose at anytime during the day in nonpregnant patients

SUPPLIED:
Cream, vaginal, as phosphate:
Cleocin®: 2% (40 g) [contains benzyl alcohol and mineral oil; packaged with 7 disposable applicators]

Clindesse™: 2% (5 g) [contains mineral oil; prefilled single disposable applicator]

Suppository (ovule), vaginal, as phosphate (Cleocin®): 100 mg (3s) [contains oleaginous base; single reusable applicator]

metronidazole (Metrogel):

Trichomoniasis: Oral: 250 mg every 8 hours for 7 days or 375 mg twice daily for 7 days or 2 g as a single dose

Bacterial vaginosis:
Oral: 750 mg (extended release tablet) once daily for 7 days

Vaginal: 1 applicatorful (~37.5 mg metronidazole) intravaginally once or twice daily for 5 days; apply once in morning and evening if using twice daily, if daily, use at bedtime

SUPPLIED:
Capsule (Flagyl®): 375 mg

Cream, topical: 0.75% (45 g)
MetroCream®: 0.75% (45 g)

Noritate®: 1% (60 g)
Emulsion, topical (Rozex™): 0.75% (60 g) [contains benzyl alcohol]

Gel, topical (MetroGel®): 0.75% (45 g)
Gel, vaginal (MetroGel-Vaginal®): 0.75% (70 g)

Lotion, topical (MetroLotion®): 0.75% (60 mL)
Tablet (Flagyl®): 250 mg, 500 mg
Tablet, extended release (Flagyl® ER): 750 mg

Vulvovaginal candidiasis:

butoconazole (Femstat):

Adults: Female:
Femstat®-3 [OTC]: Insert 1 applicatorful (~5 g) intravaginally at bedtime for 3 consecutive days

Gynazole-1®: Insert 1 applicatorful (~5 g) intravaginally as a single dose; treatment may need to be extended for up to 6 days in pregnant women (use in pregnancy during 2nd or 3rd trimester only)

SUPPLIED:
Cream, vaginal, as nitrate:
Mycelex®-3: 2% (5 g) [prefilled applicator], (20 g) [with disposable applicator]
Gynazole-1®: 2% (5 g) [prefilled applicator]

clotrimazole (mycelex, Gyne-Lotrimin)

Vaginal:

Cream:
1%: Insert 1 applicatorful vaginal cream daily (preferably at bedtime) for 7 consecutive days
2%: Insert 1 applicatorful vaginal cream daily (preferably at bedtime) for 3 consecutive days

Tablet: Insert 100 mg/day for 7 days or 500 mg single dose

Topical (cream, solution): Apply to affected area twice daily (morning and evening) for 7 consecutive days

SUPPLIED:
Combination pack (Mycelex®-7): Vaginal tablet 100 mg (7s) and vaginal cream 1% (7 g)
Cream, topical: 1% (15 g, 30 g, 45 g)

Cream, vaginal: 2% (21 g)
Mycelex®-7: 1% (45 g)
Solution, topical: 1% (10 mL, 30 mL)

Tablet, vaginal (Gyne-Lotrimin® 3): 200 mg (3s)

miconazole (Monistat):

Vaginal: Adults:
Vulvovaginal candidiasis:
Cream, 2%: Insert 1 applicatorful at bedtime for 7 days.
Cream, 4%: Insert 1 applicatorful at bedtime for 3 days.
Suppository, 100 mg: Insert 1 suppository at bedtime for 7 days.
Suppository, 200 mg: Insert 1 suppository at bedtime for 3 days.
Suppository, 1200 mg: Insert 1 suppository (a one-time dose); may be used at bedtime or during the day.

SUPPLIED:
Combination products: Miconazole nitrate vaginal suppository 200 mg (3s) and miconazole nitrate external cream 2%; Miconazole nitrate vaginal suppository 100 mg (7s) and miconazole nitrate external cream 2%

Monistat® 1 Combination Pack: Miconazole nitrate vaginal insert 1200 mg (1) and miconazole external cream 2% (5 g) [Note: Do not confuse with 1-Day™ (formerly Monistat® 1) which contains tioconazole]

Monistat® 3 Combination Pack: Miconazole nitrate vaginal suppository 200 mg (3s) and miconazole nitrate external cream 2%

Monistat® 3 Cream Combination Pack: Miconazole nitrate vaginal cream 4% and miconazole nitrate external cream 2%

Monistat® 7 Combination Pack:
Miconazole nitrate vaginal suppository 100 mg (7s) and miconazole nitrate external cream 2%

Miconazole nitrate vaginal cream 2% (7 prefilled applicators) and miconazole nitrate external cream 2%

Cream, topical, as nitrate: 2% (15 g, 30 g, 45 g)
Cream, vaginal, as nitrate [prefilled or with single refillable applicator]: 2% (45 g)
Femizol-M™: 2% (47 g)
Monistat® 3: 4% (15 g, 25 g)
Monistat® 7: 2% (45 g)

Liquid, spray, as nitrate (Micatin®): 2% (90 mL, 105 mL)
Lotion, powder, as nitrate (Zeasorb®-AF): 2% (56 g) [contains alcohol 70%]
Ointment, topical, as nitrate: (Aloe Vesta® 2-n-1 Antifungal): 2% (60 g, 150 g)
Powder, topical, as nitrate:
Lotrimin® AF, Micatin®, Micro-Guard®: 2% (90 g)
Mitrazol™: 2% (30 g)
Zeasorb®-AF: 2% (70 g)

Suppository, vaginal, as nitrate: 100 mg (7s); 200 mg (3s)
Monistat® 3: 200 mg (3s)
Monistat® 7: 100 mg (7s)

terconazole (Terazol):

Adults: Female:
Terazol® 3 vaginal cream: Insert 1 applicatorful intravaginally at bedtime for 3 consecutive days

Terazol® 7 vaginal cream: Insert 1 applicatorful intravaginally at bedtime for 7 consecutive days

Terazol® 3 vaginal suppository: Insert 1 suppository intravaginally at bedtime for 3 consecutive days

SUPPLIED:
Cream, vaginal:
Terazol® 7: 0.4% (45 g) [packaged with measured-dose applicator]
Terazol® 3: 0.8% (20 g) [packaged with measured-dose applicator]
Suppository, vaginal (Terazol® 3): 80 mg (3s)

tioconazole (Vagistat):

Local treatment of vulvovaginal candidiasis
Adults: Vaginal: Insert 1 applicatorful in vagina, just prior to bedtime, as a single dose

SUPPLIED:
Ointment, vaginal: 6.5% (4.6 g) [with applicator]

Disclaimer

Listed dosages are for - Adult patients ONLY. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. GlobalRPH does not directly or indirectly practice medicine or provide medical services and therefore assumes no liability whatsoever of any kind for the information and data accessed through the Service or for any diagnosis or treatment made in reliance thereon.

David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc.